March 3, 2010 / 8:39 AM / 10 years ago

Novo Nordisk says FDA approves growth hormone pen

COPENHAGEN, March 3 (Reuters) - The U.S. Food and Drug Administration has approved Danish drugmaker Novo Nordisk’s (NOVOb.CO) growth hormone injection pen Norditropin Flexpro, the company said on Wednesday.

Norditropin Flexpro is a prefilled growth hormone injection pen that can be used by children and adults and is intended to make daily injections easier, Novo Nordisk said.

Novo Nordisk introduced the growth hormone Norditropin in 1988 and launched its first prefilled injection pen, Norditropin Nordiflex, in 2004, the company said.

Editing by Erica Billingham

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below